Overview

• The test examines methylated cell-free DNA fragments from circulating dying cells to identify both the presence and source of transplant injury.
• Researchers analyzed 130 blood samples from 44 liver transplant patients to validate the assay’s accuracy.
• The liquid biopsy approach offers a less invasive and potentially more comprehensive alternative to traditional liver biopsies.
• Georgetown University has filed patents naming co-inventors Wellstein, Kroemer and McNamara as the technology moves toward clinical translation.
• Ongoing studies are evaluating the test’s applicability in other organ transplants and in monitoring damage during cancer treatments.